8月6日 - ** 药物开发商Avidity Biosciences RNA.O股价上涨17.6%至44.99美元
** 据英国《金融时报》报道，瑞士制药商诺华NOVN.S已向美国生物技术公司Avidity提出收购要约 (link)，以促进其药物管线的发展。
** 作为一项政策，我们不对谣言或猜测发表评论"- Avidity
** 根据 LSEG 的数据，Avidity 的市值为 46.1 亿美元。
** 包括本交易日的走势在内，该股今年以来的涨幅约为 23
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.